Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Glaukos (GKOS) Stock Right Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod

by Zacks Equity Research

Abiomed's (ABMD) Impella RP with SmartAssist gets the highest level of approval from the FDA for treatment of right heart failure.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.

Here's Why You Should Retain Ecolab (ECL) Stock Right Now

by Zacks Equity Research

Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness remains a woe.

Fresenius Medical's (FMS) Training Center to Boost Patient Care

by Zacks Equity Research

Fresenius Medical (FMS) inaugurates new training center in Korea to help in the improvement of patient care by offering comprehensive education programs for healthcare professionals.

Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DaVita (DVA) on its slew of tie-ups and strength in its kidney care business.

Trina Mukherjee headshot

Cybersecurity Gains Prominence in Healthcare: 3 Stocks to Watch

by Trina Mukherjee

Here we look at three stocks, VEEV, HSIC and BDX, that investors can keep a watch on the back of their robust cybersecurity measures.

Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive

by Zacks Equity Research

Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.

Baxter (BAX) Unveils New Digital Health Module for PD Patients

by Zacks Equity Research

Baxter (BAX) introduces new clinical management resource within the Sharesource remote patient management platform for home dialysis patients.

Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

by Zacks Equity Research

Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.

Baxter International (BAX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 18.75% and 1.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

Medical Products' Apr 29 Earnings Roster: TMO, BAX & More

by Trina Mukherjee

The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.

Why Baxter (BAX) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Baxter (BAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.

Baxter International (BAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from robust Invisalign aligners and iTero scanners shipment volume in Q1.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on the back of product launches and impressive geographical growth.

DaVita (DVA) Partners With Fresenius, Boost Home Dialysis Care

by Zacks Equity Research

DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use.

Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine

by Zacks Equity Research

Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.

Why Is Baxter (BAX) Up 1.1% Since Last Earnings Report?

by Zacks Equity Research

Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.

Baxter International (BAX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 5.26% and 0.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.

Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.